Autoimmune rheumatic diseases afflict 2--3 % of the population \[[@CR1]\] and create enormous burden on individuals and society due to poor quality of life and lower productivity \[[@CR2]\]. This heterogeneous group of clinical conditions are typically linked by the presence of autoantibodies directed against self-constituents. Often, serum autoantibodies are the only objective serological markers for an underlying rheumatic disease and as such, are part of classification criteria developed to provide a common language for diagnosis, monitoring, therapeutic trials, and international publications. While patient history and physical examination are the cornerstone of the differential diagnosis, current practice analysis shows that most clinicians readily act only after receiving confirmatory or exclusionary laboratory test results \[[@CR3], [@CR4]\].

Traditionally, the consultative and diagnostic services in rheumatology are not considered clinical emergencies that would require same-day diagnostic or clinical decisions. While this may hold true for chronic and non-inflammatory conditions, it should also be recognized that most inflammatory and autoimmune conditions that constitute a major part of academic or private rheumatology practice have to be diagnosed and acted upon quickly to curb irreversible immune-mediated damage and mortality. This is especially true for patients whose management includes critical care and aggressive therapy after diagnosis. Currently, it is necessary to use the services of centralized laboratories to obtain this information, which can delay diagnosis and appropriate treatment.

It has been estimated that 10--25 % of all patients with rheumatologic disorders visiting the emergency departments require hospital admission, and up to one-third of the hospitalized patients need intensive care \[[@CR5], [@CR6]\]. These emergencies may present as a rapidly evolving and confusing multisystem organ failure, can mimic other conditions or initially mislead with deceptively benign clinical signs. High level of suspicion, clinical knowledge, and detection of circulating autoantibody markers contribute significantly to a timely diagnosis. Table [1](#Tab1){ref-type="table"} summarizes the use of specific autoantibody testing for the diagnostic process in acute clinical settings. Test selection and interpretation of results is often dependent on the observed clinical complexity, but a characteristic combination of particular clinical and timely laboratory features help to refine the pretest assessment of disease probability. Both positive and negative predictive values of a test result may be useful. For example, a patient visiting the ER with extensive palpable purpura may trigger suspicion of systemic vasculitis, which could be directly supported by a positive ANCA test. Unfortunately, laboratory tests for autoimmune disorders require significant processing time; most autoimmune serology tests performed in reference laboratories take at least several days. Turnaround times for tests ordered by practices in remote or outreach clinics are longer, as much as 7 days.Table 1Autoimmune serology assessment for possible rheumatic disease in emergency settingsSymptomPositive test resultDiseaseAirway problems HemoptysisAnti-dsDNA, other lupus serologiesAlveolar hemorrhage in SLE Airflow obstructionAnti-CCP, RFCricoarytenoid arthritis in rheumatoid arthritis (RA) Mucopurulent rhinorrhea; subglottic stenosis; hypopharyngeal ulcerationsAnti-neutrophil cytoplasmic antibodies (ANCA, MPO or PR3)Wegener's granulomatosis Stridor, laryngotracheal stricturesAnti-type II collagenRelapsing polychondritis Acute pneumonitisAnti-dsDNA, other lupus serologiesSLEPulmonary--renal problems Pulmonary hemorrhage and acute renal failureAnti-GBM, MPO-ANCA, PR3-ANCAGoodpasture's syndrome; systemic vasculitisNeuropsychiatric problems Encephalopathy, psychosis, focal central nervous system diseaseAnti-*N*-methyl-[d]{.smallcaps}-aspartate receptor (NMDA-R), anti-ribosomal P antibodies, antiphospholipid antibodiesNeuropsychiatric SLE, antiphospholipid syndrome Weakness, paralysis, bilateral sensory deficit, impaired sphincter controlLupus serologiesTransverse myelitis in SLE SeizuresAnti-dsDNA, other lupus serologiesLupus cerebritisThromboembolic problems DVT, pulmonary thromboembolism, fetal loss, retinal artery occlusionAnti-phospholipid antibodiesAntiphospholipid syndromeNeuromuscular problems Progressive symmetric muscle weakness; dysphagia; dysphoniaAnti-Jo-1, other myositis-specific autoantibodiesDermatomyositis, polymyositis Unusual weakness and hypokalemiaAnti-Ro/SSA; anti-La/SSBSjogren's syndrome hypokalemic paralysisCardiac problems Pleuritic or positional chest pain, dyspnea, tachycardiaAnti-dsDNA, other lupus serologies, Anti-phospholipid antibodiesSLE pleuro-pericarditis, pericardial tamponade Congenital heart block; neonatal carditisAnti-Ro/SSA; anti-La/SSBNeonatal SLERenal problems Rapidly progressive renal failureMPO-ANCA, PR3-ANCA, anti-dsDNA and other lupus serologies, anti-phospholipid antibodiesMicroscopic polyangiitis, WG, lupus nephritis, catastrophic antiphospholipid syndrome Accelerated hypertensionAnti-Scl-70; anti-centromeres, anti-RNA-Polymerase IIIRenal crisis in systemic sclerosisJoint problems Pain, stiffness, swelling with symptoms of systemic diseaseAnti-CCP, RF and lupus serologiesRA, SLEOcular problems Red, painful, photophobic eyeRF, anti-CCP, lupus serologiesRA, Behcet's, juvenile RA, SLEGastrointestinal problems Colicky abdominal painLupus serologiesSLE mesenteric arteritisSkin problems Petechiae, palpable purpura, hemorrhagic blisters, ulcerations and gangreneSLE and RA serologiesSLE, rheumatoid vasculitis Neonatal skin rashAnti-Ro/SSA, anti-La/SSBNeonatal lupusHematological problems Anemia, thrombocytopenia, leukopeniaAnti-DNA and lupus serologies; anti-erythrocyte, anti-platelet antibodiesSLE, autoimmune hemolytic anemia ThrombocytopeniaAntiphospholipid antibodiesAntiphospholipid syndrome

The outpatient rheumatology practice of dealing with autoimmune conditions collides with a different problem: assessing active disease resulting in progressive organ damage and early mortality. Establishing reliable biomarkers that accurately predict disease activity is a major challenge faced by practicing physicians. Such tests should be clinically meaningful, affordable, and easy, and should distinguish cross-sectional differences between patients with active and inactive disease as well as longitudinal changes in disease expression or activity in individual patients \[[@CR7]\].

Quantitative measures of autoimmune activity, in contrast to critical care analytes, are generally not considered important in the biomarker field, as changes in autoantibody concentration are believed to be slow and of minor importance to the patient outcome. This misconception is particularly apparent in the rapid humoral immune response observed in autoimmune loop conditions like SLE and antiphospholipid syndrome \[[@CR8], [@CR9]\]. However, serial and routine testing in a cost-effective and readily accessible way requires technology and assays that currently do not exist.

Previous research suggests that some of the autoantibodies listed in Table [1](#Tab1){ref-type="table"} as diagnostic aids behave like parameters that wax and wane with disease activity, thus holding promise to provide prognostic clinical information and, when at their best, to guide therapy. When target organ involvement is considered, autoantibodies may correlate with important clinical outcomes. Current candidate autoantibody disease activity markers are summarized in Table [2](#Tab2){ref-type="table"}. The more recently described value of regular autoantibody "profiling" in patients with Wegener's granulomatosis due to change in epitope specificity of PR3-ANCA during active disease \[[@CR10]\] and the association of high and low anti-NMDA-R autoantibody titers with unique CNS symptoms in neuropsychiatric SLE \[[@CR11]\] underscores the importance of autoantibody assays for optimal management.Table 2Associations between autoantibody changes and disease activityDisease/conditionAutoantibodyChangeClinical predictionSystemic lupus erythematosusAnti-dsDNA⇑Active flare \[[@CR15]--[@CR17]\]Anti-dsDNA⇓Active flare \[[@CR18]\]Anti-nucleosome⇑Active disease/lupus nephritis \[[@CR19]--[@CR21]\]Anti-C1q⇑Lupus nephritis \[[@CR22]--[@CR24]\]/active disease \[[@CR25]\]Anti-NMDA-R⇑Permanent CNS impairment \[[@CR26], [@CR27]\]Anti-NMDA-R⇓Transient CNS symptoms \[[@CR26], [@CR27]\]Anti-CRP⇑Lupus nephritis/response to therapy \[[@CR28]\]Anti-interferon-α⇓Inactive disease \[[@CR29]\]Systemic vasculitisAnti-PR3⇑Active disease/disease relapse \[[@CR30]--[@CR32]\]Anti-MPO⇑Active disease/disease relapse \[[@CR33], [@CR34]\]Anti-GBM⇑Active disease/disease relapse \[[@CR35], [@CR36]\]SclerodermaAnti-topoisomerase I⇑Active scleroderma \[[@CR37]--[@CR39]\]Rheumatoid arthritisAnti-drug (adalimumab)⇑Treatment failure \[[@CR40]\]Antiphospholipid syndrome/SLEAnti-phospholipid⇑Procoagulant state, thrombosis \[[@CR41]--[@CR43]\]Necrotizing myopathyAnti-signal recognition particle⇑Decreased muscle strength, increased creatine kinase activity \[[@CR44]\]Thrombotic thrombocytopenic purpuraAnti-ADAMTS13 antibodies⇑Disease relapse \[[@CR45], [@CR46]\]Pregnancy in SLEAnti-Ro(SSA)/anti-Ro52⇑Congenital heart block \[[@CR47], [@CR48]\]Anti-La(SSB)⇑Neonatal lupus \[[@CR49]\]Autoantibody serum screeningAnti-DFS70⇑ANA-positive healthy individuals \[[@CR50], [@CR51]\]

It is beyond the scope of this paper to discuss discrepancies observed among studies that characterize autoantibodies as disease activity markers. Many believe that lack of prospective or longitudinal studies, clearly defined methodology, patient selection bias, use of inconsistent definitions for disease activity, frequency of testing, and effects of therapy contribute to conflicting results \[[@CR12], [@CR13]\]. It should also be noted that disease activity, disease severity, and the ensuing irreversible damage should be conceptually differentiated, and measurement tools for these parameters may be different \[[@CR14]\]. Despite these potential problems in interpreting laboratory results, the need of clinicians to judge disease activity has made the practice of ordering autoantibodies widespread and frequent, with 92 % of US rheumatologists using serial anti-dsDNA autoantibody titers to monitor disease activity in SLE \[[@CR4]\].

New technologies, that deliver quantitative information in a simple, fast, and low-cost fashion when combined with frequent visits and blood sampling may provide for the first time a tool to definitively establish the predictive value of autoantibody fluctuations in disease flares. Point-of-care (POC) testing, otherwise referred as near patient, bedside or extra-laboratory testing for clinically important analytes, has gathered strength in diverse medical specialties. By virtue of its near real-time data collection capability, POC testing has the potential to change the paradigm in the practice of medicine, and we anticipate that rheumatology will not be an exception.

Devising a reliable assay for measuring a specific antibody in human serum is more difficult than measuring most non-antibody analytes in biological fluids, because any one antibody specificity is usually a tiny fraction of total serum immunoglobulin. Non-specific binding of immunoglobulin may have impeded the development of a reliable antibody biosensor. However, recent and evolving advances in the field of immunosensor technologies have provided high accuracy in quantification and low detection limit in testing for some autoantibodies used in clinical practice.

Current POC immunoassay technologies come in various configurations and complexities. Table [3](#Tab3){ref-type="table"} provides a partial list of new biosensors and their platforms that have the potential to measure autoantibodies in "real" clinical samples. Surface plasmon resonance-based sensors are the most rapid method, but will require adaptation to inexpensive miniaturized devices. Lateral flow based methods will probably be restricted to non-quantitative readouts. Devices that required specialized antigen tags may have limited practical potential. Electrochemical amplification methods using readily available autoantigens are especially promising. Autoantibody biosensors have generally equaled or surpassed traditional central laboratory methods in performance metrics, such as sensitivity, specificity, and especially time to result. Advances in the development and application of portable, antibody-based immunosensors are presented in several recent review papers \[[@CR52]--[@CR56]\].Table 3Devices with potential to measure autoantibodies (Ab) at point-of-careAutoantibodyDetection technology/assay platformAssay durationReferencesAnti-dsDNAElectrochemical reduction of redox-tagged probe/Ab inhibition in single-step cell\~45 min\[[@CR60]\]Decreased resonance frequency/piezoelectric quartz crystal microbalance\<60 min\[[@CR61]\]Refractive index change/surface plasmon resonance sensor chip\~5 min\[[@CR62]\]Anti-CCPFormation of visual line by colored nanoparticles/lateral flow chromatography10 min\[[@CR66]\]Refractive index change/surface plasmon resonance sensor chip\~5 min\[[@CR67]\]Anti-chromatinPeroxidase-mediated electrochemical amplification/flow-through cell20 min\[[@CR64]\]Anti-IgG (RF) Anti-MCVFormation of visual line by colored nanoparticles/lateral flow chromatography15 min\[[@CR65]\]Anti-Ro/SSA, Anti-Ro52, Anti-La/SSBLuminescence by luciferase-tagged probe/bead immobilized Ab in two-step cells25 min\[[@CR63]\]Anti-β2-glyco-protein IRefractive index change/surface plasmon resonance sensor chip\~5 min\[[@CR68]\]

The American College of Rheumatology (ACR) has recognized the value of decentralized laboratory testing in their position statement on the issue \[[@CR57]\] in which not only patient convenience (a single site for physician contact and serology testing), but also cost savings associated with return visits just to implement treatment options would be benefited. According to the ACR, rheumatologists, in directing their office laboratories, are the most qualified for determining the utility of specific tests, analyzing their results and applying these results to therapeutic situations. Immediate autoantibody diagnostics can also help to establish autoimmune disease units in hospitals, as recently suggested \[[@CR58], [@CR59]\].

Sites for POC serology testing could include outpatient rheumatology clinics, intensive care units, and emergency or urgent care facilities, as well as hospital infusion centers. Another attractive possibility is the use of POC serology testing in field-based, remote or rudimentary clinical settings, thereby bringing laboratory-based medicine to low-resource areas. In all these environments, POC devices would be of value to rheumatology physicians, who can immediately act on the information. In the outpatient clinic, a rapid test result could affect physician evaluation of the patient, thereby facilitating action and likely improving the usefulness of the office visit. POC methods should enhance patient compliance for laboratory testing and decrease the number of return visits. The efficiency and quality of health care from both the physician and the patient perspective is likely to improve as a result.

At this point it is unlikely that POC testing will replace the traditional central clinical laboratory model in all situations. Establishing rigid quality control of POC testing that satisfies regulatory requirements and oversight could be challenging. Handling and disposal of potentially biohazardous and chemical fluids may need to be addressed. Physical records, transfer of test results into a patient chart, and reimbursement issues will also play a major role in acceptance of POC technology.

POC serology testing is truly a work in progress, and its successful deployment requires a long-term commitment. The anti-CCP assay has recently been commercialized, but general acceptance of POC autoantibody testing in rheumatology has yet to happen. The optimum technology should be reliable, fast, inexpensive, quantitative, and easy to put in place and use. The latter features will make POC testing attractive to clinical rheumatology staff whose primary focus is patient care. Analyses of health care in the future predict that medicine will be more decentralized, and realization of POC testing has the promise to accelerate this paradigm shift for patient management.

ADAMTS13

:   A desintegrin and metalloproteinase with a trombospondin type 1 motif, member 13
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:   C-reactive protein
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DVT

:   Deep venous thrombosis
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:   Glomerular basement membrane
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:   Mutated citrullinated vimentin
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:   Myeloperoxidase

NMDA-R

:   *N*-methyl-[d]{.smallcaps}-aspartate receptor
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:   Neuropsychiatric systemic lupus erythematosus

POC

:   Point-of-care

PR3

:   Proteinase 3

RA

:   Rheumatoid arthritis

RF

:   Rheumatoid factor

SLE

:   Systemic lupus erythematosus
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